Cordlife Group Limited at a glance

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia with extensive transplant experience, having processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples.

Cordlife is an industry leader in Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening. Cordlife strives to ensure reliable quality and is committed to a customer-centric approach.

At Cordlife, our primary commitment revolves around two key areas: ensuring reliable quality and placing you, our valued customer, at the centre of everything we do. Our mission is to make transfusion medicine and biotherapies safe, available, and effective on a global scale. We strive to maintain the highest standards in cord blood banking for your confidence and well-being.

In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India is one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement.

About Cordlife India

Cordlife India is a fully owned subsidiary of Cordlife Group Limited. The Indian Laboratory is AABB accredited and operates the most advanced umbilical cord and cord blood processing, testing and cryopreservation facility in the country, with a storage capacity of 200,000 cord blood units scalable by another few lakh units.

The state-of-the-art laboratory is equipped with the latest and the most modern equipment and has recently upgraded from the automated Sepax®2 to the FDA approved AXP®II. Its MNC (Mono Nuclear Cells) and CD34+ recovery rate is higher.^[1]

It maintains a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Located within a natural calamity proof building, the facility is also built with continuous power backup and round-the-clock surveillance system. Cordlife operates in more than 210 cities across India, making it one of the largest stem cell banking companies locally.

References:
1. Christy Kim et al. Meta-analysis of the AXP® and SEPAX® automated cord blood processing systems. CESCA Therapeutics White Paper; 2015.